The International Space Station National Laboratory (ISS National Lab) and NASA have unveiled a new National Lab Research Announcement (NLRA), offering up to $4 million in funding for projects that utilize space environments to advance disease therapies. The solicitation targets research that enhances models for studying diseases and developing treatments, particularly in areas such as cancer, cardiovascular, neurodegenerative, and muscle and bone diseases. The microgravity environment of the ISS can accelerate disease modeling, potentially overcoming common challenges in translating research into clinical applications.
The joint initiative emphasizes projects focused on drug development, including screening, delivery, and addressing drug resistance and toxicity. NASA and the ISS National Lab are keen on supporting innovative approaches that leverage space technology, including nanotechnology, to create therapies that can address population and disease heterogeneity on Earth. The NLRA solicitation is open until March 3, 2025, allowing researchers ample time to submit proposals that could lead to groundbreaking advancements in disease treatment.
Beyond the ISS National Lab and NASA, other organizations like the Translational Research Institute for Space Health (TRISH) are also contributing to space-based health research. TRISH's Catalyst Grant Program is an ongoing opportunity for innovative projects that may fall outside traditional research scopes, further highlighting the growing interest in space as a platform for pioneering health solutions. Partnerships with companies like SpaceX, LevelEx, and XRHealth underscore the potential of space technology to drive significant advancements in medical science.
Click here to read the original news story.